Arseus H1 profit beats expectations led by drug ingredients
BRUSSELS Aug 2 (Reuters) - Belgian medical equipment maker Arseus posted better-than-expected core profit in the first half of 2013, led by a surge in profitability at its Fagron unit which sells medical ingredients to pharmacies.
Recurring core profit (REBITDA) rose 29.9 percent in the first-half of 2013 to 50.4 million euros ($66.70 million), it said on Friday. That was better than the 45 million euros expected in a Reuters consensus.
It said that for 2013 it expected healthy organic growth with profitability growing faster than turnover. ($1 = 0.7557 euros) (Reporting by Robert-Jan Bartunek)
- Malaysia plane search straddles continent as police focus on crew |
- Crimeans vote over 90 percent to quit Ukraine for Russia |
- Moscow wins overwhelming Crimea vote, West readies sanctions |
- Ukraine, Russia agree Crimea truce until March 21-Ukraine minister
- Stocks near one-month low as western sanctions on Russia loom |